The data presented covered everything from its mainstay acalabrutinib, sold as Calquence, to the eye-catching AZD0120, an ...

The pharmaceutical company said its ceralasertib combination didn’t meet the primary goal of a late-stage clinical trial for ...

AstraZeneca ( ($GB:AZN) ) has issued an announcement. AstraZeneca has confirmed that, as of 31 December 2025, its issued share capital with voting ...

U.K.-based AstraZeneca has scored the exclusive rights to develop and commercialize the pan-KRAS inhibitor, dubbed JAB-23E73, outside China. On Jacobio’s home territory, the Beijing-headquartered ...

Pharma giant AstraZeneca has expanded its supply deal with Michigan-based medical radioisotope producer Niowave, establishing ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche's drug, Perjeta, for the first-line treatment of patients with a type of ...

AstraZeneca will end U.S. commercial sales of Andexxa Dec. 22, citing safety concerns raised in postmarketing data and a recent trial, according to a ...

While AstraZeneca has announced that it will participate in the 2026 JP Morgan Healthcare Conference, it hasn’t yet revealed details about its presentation.

AstraZeneca has delivered on CEO Pascal Soriot’s promise to grow revenues to more than $40 billion by 2023. Now, the chief exec is already mapping out his next goal. AZ’s global revenue in 2022 ...

AstraZeneca said on Monday that a late‑stage trial testing its blockbuster therapy Imfinzi in combination with its ...

FDA approves AstraZeneca and Daiichi's Enhertu combo for first-line HER2-positive breast cancer, while the EU clears Saphnelo self-injection for lupus.

AstraZeneca’s investigational ATR kinase inhibitor did not improve overall survival when combined with Imfinzi in patients with non-small cell lung cancer during a Phase III clinical trial, the ...